VEGFA and glioblastoma: Griveau et al. reported an increased Wnt7a expression in human GBM patient biopsies after bevacizumab treatment and a selection for the Olig2+/Wnt7+ phenotype in a mouse model following prolonged anti-VEGF therapy [30].